# Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).

> **NCT05116189** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 643 (actual)

## Conditions studied

- Ovarian Cancer
- Carcinoma, Ovarian Epithelial
- Fallopian Tube Neoplasms

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Paclitaxel
- **DRUG:** Bevacizumab
- **OTHER:** Placebo for pembrolizumab
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT05116189
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-12-13
- **Primary completion:** 2025-03-05
- **Final completion:** 2027-07-16
- **Target enrollment:** 643 (ACTUAL)
- **Last updated:** 2026-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05116189

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05116189, "Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05116189. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*